PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24438818-17	2014	(68)Ga-DOTA-NGR could also specifically bind to the APN receptor in vitro and in vivo, and might be a potential molecular probe for the noninvasive detection of APN-positive tumors and neovasculature.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	7-11	alanyl aminopeptidase, membrane	Homo sapiens	52-55	
24438818-17	2014	(68)Ga-DOTA-NGR could also specifically bind to the APN receptor in vitro and in vivo, and might be a potential molecular probe for the noninvasive detection of APN-positive tumors and neovasculature.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	7-11	alanyl aminopeptidase, membrane	Homo sapiens	161-164	
23190134-8	2013	For small animal microPET studies, (64)Cu-DOTA-NGR2 displayed more favorable in vivo performance in terms of higher tumor uptake and slower tumor washout in CD13-positive HT-1080 tumor xenografts as compared to (64)Cu-DOTA-NGR1.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	39-46	alanyl aminopeptidase, membrane	Homo sapiens	157-161	
23190134-9	2013	As expected, significantly lower tumor uptake and poorer tumor/normal organ contrast were observed for both (64)Cu-DOTA-NGR1 and (64)Cu-DOTA-NGR2 in CD13-negative HT-29 tumor xenografts in comparison with those in the HT-1080 tumor xenografts.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	133-140	alanyl aminopeptidase, membrane	Homo sapiens	149-153	
23190134-10	2013	The CD13-specific tumor activity accumulation of both (64)Cu-DOTA-NGR1 and (64)Cu-DOTA-NGR2 was further demonstrated by significant reduction of tumor uptake in HT-1080 tumor xenografts with a coinjected blocking dose of cyclic NGR peptide [c(CNGRC)].	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	58-65	alanyl aminopeptidase, membrane	Homo sapiens	4-8	
23190134-10	2013	The CD13-specific tumor activity accumulation of both (64)Cu-DOTA-NGR1 and (64)Cu-DOTA-NGR2 was further demonstrated by significant reduction of tumor uptake in HT-1080 tumor xenografts with a coinjected blocking dose of cyclic NGR peptide [c(CNGRC)].	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	79-86	alanyl aminopeptidase, membrane	Homo sapiens	4-8	
23190134-12	2013	We concluded that both (64)Cu-DOTA-NGR1 and (64)Cu-DOTA-NGR2 have good and specific tumor uptake in CD13-positive HT-1080 tumor xenografts.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	27-34	alanyl aminopeptidase, membrane	Homo sapiens	100-104	
23190134-12	2013	We concluded that both (64)Cu-DOTA-NGR1 and (64)Cu-DOTA-NGR2 have good and specific tumor uptake in CD13-positive HT-1080 tumor xenografts.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	48-55	alanyl aminopeptidase, membrane	Homo sapiens	100-104	
23190134-14	2013	(64)Cu-DOTA-NGR2 is a promising PET probe for noninvasive detection of CD13 receptor expression in vivo.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	4-11	alanyl aminopeptidase, membrane	Homo sapiens	71-75